Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Bergmark et al. (Sun,) studied this question.

www.synapsesocial.com/papers/68e700f4b6db64358767b7c6 — DOI: https://doi.org/10.1056/nejmoa2402309

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk· 2021 · 200 citations
2. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia· 2023 · 45 citations
3. Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms· 2023 · 43 citations
4. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society· 2021 · 872 citations
5. Analysis of Longitudinal Trials with Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation· 2013 · 288 citations